Back to School: How biopharma can reboot drug development. Access exclusive analysis here

MN-305: Phase IIa data

MNOV said it will discontinue development of MN-305 for insomnia after the compound missed the primary endpoint

Read the full 173 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE